CL2017000494A1 - Tratamientos médicos a base de anamorelina. - Google Patents
Tratamientos médicos a base de anamorelina.Info
- Publication number
- CL2017000494A1 CL2017000494A1 CL2017000494A CL2017000494A CL2017000494A1 CL 2017000494 A1 CL2017000494 A1 CL 2017000494A1 CL 2017000494 A CL2017000494 A CL 2017000494A CL 2017000494 A CL2017000494 A CL 2017000494A CL 2017000494 A1 CL2017000494 A1 CL 2017000494A1
- Authority
- CL
- Chile
- Prior art keywords
- anamorelin
- anamoreline
- cancer
- medical treatments
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Nutrition Science (AREA)
- Addiction (AREA)
- Psychiatry (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Otolaryngology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Abstract
<p>SE DESCRIBEN MÉTODOS DE TRATAMIENTO DE AFECCIONES RELACIONADAS CON EL CÁNCER USANDO ANAMORELINA. LA MODALIDAD PRINCIPAL SE RELACIONA CON LA AFECCIÓN ÚNICA DE PACIENTES QUE LA DEFINEN MEDIANTE EL TRATAMIENTO DE LA CAQUEXIA EN UN PACIENTE HUMANO CON CÁNCER, QUE COMPRENDE LA ADMINISTRACIÓN A DICHO PACIENTE DE UNA CANTIDAD TERAPÉUTICAMENTE EFECTIVA DE ANAMORELINA DURANTE UN PERÍODO TERAPÉUTICAMENTE EFECTIVO, Y LA SORPRENDENTE CAPACIDAD OBSERVADA DE LA ANAMORELINA DE AUMENTAR LA MASA CORPORAL MAGRA DE ESTA POBLACIÓN.</p>
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462045976P | 2014-09-04 | 2014-09-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017000494A1 true CL2017000494A1 (es) | 2017-09-15 |
Family
ID=55436476
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017000494A CL2017000494A1 (es) | 2014-09-04 | 2017-03-02 | Tratamientos médicos a base de anamorelina. |
Country Status (44)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9492535B2 (en) | 2013-03-14 | 2016-11-15 | Aimmune Therapeutics, Inc. | Peanut formulations and uses thereof |
| DK3188599T3 (da) | 2014-09-04 | 2019-11-25 | Helsinn Healthcare Sa | Medicinske behandlinger baseret på anamorelin |
| EP3836801A4 (en) | 2018-08-16 | 2022-05-18 | Société des Produits Nestlé S.A. | MAINTENANCE DOSE ORAL PEANUT IMMUNOTHERAPY |
| JP2022514645A (ja) | 2018-12-20 | 2022-02-14 | アイミューン セラピューティクス，インコーポレイテッド | ピーナツ経口免疫療法において投与が欠落した場合の投与スケジュール |
| CN113966229A (zh) | 2019-05-10 | 2022-01-21 | 爱沐疗法公司 | 用于改善花生过敏患者的生活质量的方法 |
| CN115569120A (zh) | 2019-08-30 | 2023-01-06 | 赫尔森保健股份公司 | 具有改善稳定性的阿拉莫林片剂的生产方法 |
| BR112022005457A2 (pt) * | 2019-10-24 | 2022-06-21 | Toray Industries | Agente terapêutico ou profilático para caquexia |
| JP2024534464A (ja) * | 2021-09-17 | 2024-09-20 | 小野薬品工業株式会社 | 食欲不振／悪液質患者における患者報告アウトカムに関する臨床的に意味のある改善を判定し、提供する方法 |
| JPWO2025004650A1 (es) * | 2023-06-28 | 2025-01-02 |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6303620B1 (en) | 1998-05-11 | 2001-10-16 | Novo Nordisk A/S | Compounds with growth hormone releasing properties |
| ECSP993020A (es) | 1999-06-16 | 1999-08-12 | Terapia de combinacion para la fragilidad musculoesqueletica | |
| ECSP993021A (es) | 1999-06-16 | 1999-08-12 | Combinaciones terapeuticas para la fragilidad musculoesqueletica | |
| US20010020012A1 (en) | 2000-02-01 | 2001-09-06 | Andersen Maibritt Bansholm | Use of compounds for the regulation of food intake |
| CN1863550A (zh) * | 2003-08-06 | 2006-11-15 | 加斯特罗泰克药物公司 | 促分泌素样生长素释放肽在癌症恶病质中以及在刺激食欲方面的应用 |
| EP1660117A2 (en) * | 2003-08-06 | 2006-05-31 | Gastrotech Pharma A/S | Use of secretagogues like ghrelin in cancer cachexia and for stimulating appetite |
| EP1735055A1 (en) | 2004-03-30 | 2006-12-27 | Sapphire Therapeutics, Inc. | Method of reducing c-reactive protein using growth hormone secretagogues |
| EP2298760B1 (en) * | 2004-06-29 | 2015-08-05 | Helsinn Healthcare S.A. | Crystal forms of (3R)-1-(2-methylalanyl-D-tryptophyl)-3-(phenylmethyl)-3-piperidinecarboxylic acid 1,2,2-trimethylhydrazide |
| CA2677813A1 (en) * | 2007-02-13 | 2008-08-21 | Helsinn Therapeutics (U.S.), Inc. | Method of treating cell proliferative disorders using growth hormone secretagogues |
| TWI429436B (zh) | 2007-04-10 | 2014-03-11 | Helsinn Therapeutics Us Inc | 使用生長激素促泌素治療或預防嘔吐之方法 |
| JO3353B1 (ar) | 2012-04-20 | 2019-03-13 | Ono Pharmaceutical Co | شكل صلب معزول من أحادي هيدروكلوريد أناموريلين بنسبة مولارية منخفضة من الكلوريد: أناموريلين ومحتوى منخفض من مذيب عضوي متبقي |
| EP2854810A4 (en) | 2012-05-25 | 2016-04-06 | Raqualia Pharma Inc | GHRELIN RECEPTOR AGONISTS FOR THE TREATMENT OF ACHLORHYDRIA |
| DK3188599T3 (da) | 2014-09-04 | 2019-11-25 | Helsinn Healthcare Sa | Medicinske behandlinger baseret på anamorelin |
-
2015
- 2015-08-28 DK DK15838548T patent/DK3188599T3/da active
- 2015-08-28 CN CN201710646685.0A patent/CN107375285A/zh active Pending
- 2015-08-28 KR KR1020187020062A patent/KR102234319B1/ko active Active
- 2015-08-28 TN TN2017000040A patent/TN2017000040A1/en unknown
- 2015-08-28 ES ES15838548T patent/ES2761777T3/es active Active
- 2015-08-28 EA EA201790352A patent/EA035578B1/ru unknown
- 2015-08-28 MA MA40607A patent/MA40607B1/fr unknown
- 2015-08-28 CN CN201811119404.7A patent/CN109172575A/zh active Pending
- 2015-08-28 GE GEAP201814459A patent/GEAP201814459A/en unknown
- 2015-08-28 CR CR20170121A patent/CR20170121A/es unknown
- 2015-08-28 EP EP15838548.4A patent/EP3188599B1/en active Active
- 2015-08-28 RS RS20191688A patent/RS59751B1/sr unknown
- 2015-08-28 MX MX2017002825A patent/MX361741B/es active IP Right Grant
- 2015-08-28 CN CN202111026050.3A patent/CN113577073A/zh active Pending
- 2015-08-28 ME MEP-2019-372A patent/ME03597B/me unknown
- 2015-08-28 WO PCT/US2015/047435 patent/WO2016036598A1/en not_active Ceased
- 2015-08-28 US US14/839,038 patent/US9675600B2/en active Active
- 2015-08-28 HU HUE15838548A patent/HUE046894T2/hu unknown
- 2015-08-28 MD MDA20170025A patent/MD4710C1/ro active IP Right Grant
- 2015-08-28 PL PL15838548T patent/PL3188599T3/pl unknown
- 2015-08-28 JP JP2017512679A patent/JP6356907B2/ja active Active
- 2015-08-28 SG SG11201701567UA patent/SG11201701567UA/en unknown
- 2015-08-28 LT LT15838548T patent/LT3188599T/lt unknown
- 2015-08-28 KR KR1020177008748A patent/KR101881264B1/ko active Active
- 2015-08-28 EP EP19183144.5A patent/EP3590338A3/en not_active Withdrawn
- 2015-08-28 AP AP2017009772A patent/AP2017009772A0/en unknown
- 2015-08-28 MY MYPI2017700714A patent/MY187167A/en unknown
- 2015-08-28 SI SI201530994T patent/SI3188599T1/sl unknown
- 2015-08-28 AU AU2015312231A patent/AU2015312231B2/en active Active
- 2015-08-28 HR HRP20192345TT patent/HRP20192345T1/hr unknown
- 2015-08-28 PE PE2017000359A patent/PE20171109A1/es unknown
- 2015-08-28 KR KR1020217008765A patent/KR102307275B1/ko active Active
- 2015-08-28 UA UAA201702308A patent/UA120765C2/uk unknown
- 2015-08-28 GE GEAP201514459A patent/GEP20186939B/en unknown
- 2015-08-28 PT PT158385484T patent/PT3188599T/pt unknown
- 2015-08-28 CN CN201580059744.3A patent/CN107205389A/zh active Pending
- 2015-08-28 BR BR112017003552A patent/BR112017003552A2/pt not_active Application Discontinuation
- 2015-08-28 CA CA2959158A patent/CA2959158A1/en active Pending
- 2015-08-28 CN CN202111027023.8A patent/CN113577074A/zh active Pending
- 2015-08-30 JO JOP/2015/0210A patent/JO3541B1/ar active
- 2015-09-01 TW TW104128838A patent/TWI639429B/zh active
- 2015-09-02 UY UY0001036286A patent/UY36286A/es not_active Application Discontinuation
- 2015-09-03 AR ARP150102818A patent/AR103118A1/es unknown
-
2017
- 2017-02-20 IL IL250692A patent/IL250692B/en active IP Right Grant
- 2017-03-02 CL CL2017000494A patent/CL2017000494A1/es unknown
- 2017-03-02 PH PH12017500392A patent/PH12017500392B1/en unknown
- 2017-03-03 SV SV2017005400A patent/SV2017005400A/es unknown
- 2017-03-03 DO DO2017000055A patent/DOP2017000055A/es unknown
- 2017-03-03 NI NI201700024A patent/NI201700024A/es unknown
- 2017-03-30 EC ECIEPI201719893A patent/ECSP17019893A/es unknown
- 2017-04-03 CO CONC2017/0003263A patent/CO2017003263A2/es unknown
- 2017-05-09 US US15/590,025 patent/US10278964B2/en active Active
-
2018
- 2018-06-14 JP JP2018113592A patent/JP6923486B2/ja active Active
-
2019
- 2019-02-14 US US16/275,669 patent/US10894041B2/en active Active
- 2019-12-16 CY CY20191101321T patent/CY1122746T1/el unknown
-
2020
- 2020-12-11 US US17/119,482 patent/US11723902B2/en active Active
-
2021
- 2021-02-26 JP JP2021029775A patent/JP7044918B2/ja active Active
-
2023
- 2023-06-22 US US18/212,720 patent/US20240024303A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SV2017005400A (es) | Tratamientos mã‰dicos a base de anamorelina | |
| TWD196868S (zh) | 超音波治療手持件 | |
| MY174727A (en) | Stable, protracted glp-1/glucagon receptor co-agonists for medical use | |
| CL2018001677A1 (es) | Tratamiento de la enfermedad de fabry en pacientes no tratados y tratados previamente con ert | |
| MX2013004817A (es) | Enfermedad inflamatoria. | |
| BR112017023170A2 (pt) | dispositivo de banho medicinal e seu uso | |
| MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
| MX2020003049A (es) | Semaglutida en la terapia medica. | |
| TWD196867S (zh) | 超音波治療車 | |
| EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
| EA201071209A1 (ru) | Применение дронедарона или его фармацевтически приемлемой соли для получения лекарственного средства для регуляции уровня калия в крови | |
| GB2554591A (en) | Clinical support system and method | |
| UA108975C2 (uk) | Застосування співполімеру натрійкарбоксиметилцелюлози і госиполу в комплексній терапії пацієнтів з аутистичними розладами і когнітивними порушеннями | |
| CL2015002951A1 (es) | Silicato de zirconio microporoso y diuréticos para la reducción de potasio y el tratamiento de una enfermedad crónica del riñón y/o crónica del corazón. | |
| GT201700041A (es) | Tratamientos médicos a base de anamorelina | |
| BR112018068910A2 (pt) | sultiame para o tratamento de apneia do sono | |
| NZ713490A (en) | Oral suspension for treating eosinophilic esophagitis | |
| BR112016030291A2 (pt) | terapia de combinação | |
| LT3609486T (lt) | Sarpogrelatas, skirtas naudoti žinduolių širdies ligų gydymo būdui | |
| EA201991866A1 (ru) | Комбинированная терапия | |
| EA201692163A1 (ru) | Лекарственное средство для лечения пациентов с тиннитусом | |
| CY1119117T1 (el) | Δερμοπροστατευτικη και δερμο-εξισορροπητικη συνθεση | |
| AR081669A1 (es) | Semuloparina para uso como un tratamiento antitrombotico en cirugia ortopedica con perfil beneficio-riesgo mejorado | |
| PL417551A1 (pl) | Zastosowanie insuliny do leczenia stopy cukrzycowej w formie iniekcji bezpośredniej w chorą stopę | |
| CN105476179A (zh) | 一种施药式保健鞋垫 |